The company granted stock options to purchase an aggregate of 87,950 shares of Nurix common stock and restricted stock unit ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Scientists have developed a powerful new method for selectively and reversibly breaking connections between brain cells—a ...

Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies. As a SUMO ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid ...

SEED Therapeutics Inc. presented compelling developments from its cancer research programs at the 2025 Annual Meeting of the ...

Here, we expand the repertoire of PROTAC compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high ...

Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 2 (PTPN2; ...

Depending on the PTD–E3 ligase pairs, PROTAR influenza viruses show varying levels of attenuation in vitro. In animal models, PROTAR vaccine candidates exhibit significant attenuated ...

Depending on the PTD–E3 ligase pairs, PROTAR influenza viruses show varying levels of attenuation in vitro. In animal models, PROTAR vaccine candidates exhibit significant attenuated ...